drugset / Trial / NCT05117554

Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers

NCT05117554

Phase 1 Completed 70 enrolled Arcus Biosciences, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study will evaluate the safety and tolerability, pharmacokinetic, and pharmacodynamic profile, and drug-drug interaction (DDI) of casdatifan in healthy participants.

Timeline

Start
2021-11-09
Primary completion
2023-02-17
Completion
2023-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Casdatifan Small molecule Oral
Subject Midazolam Small molecule Oral

Indications

No indication recorded.